Immunoablative therapy with autologous stem cell transplantation in the treatment of poor risk multiple sclerosis
2001
Abstract
High-dose chemotherapy with autologous peripheral blood progenitor cell (PBPC) transplantation has been used for several years in the treatment of hematologic malignancies and some solid tumors. Each high-dose chemotherapy with PBPC support is associated with prolonged deep suppression of the immune system - immunoablation.
Immunoablative effect of the chemotherapy may be applied in the treatment of some severe forms of autoimmune diseases (AID) that do not react to conventional intensive immunosuppression